1 / 21

HSPO Monitoring Visit/Audit

HSPO Monitoring Visit/Audit. Monika Haugstetter, RN, MHA, MSN Judy Gaffney, BA HSPO/IRB University of Connecticut Health Center. http://resadm.uchc.edu/hspo/index.html. Audit Purpose. Management tool to monitor: conduct of research studies & IRB review process

linh
Télécharger la présentation

HSPO Monitoring Visit/Audit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HSPO Monitoring Visit/Audit Monika Haugstetter, RN, MHA, MSN Judy Gaffney, BA HSPO/IRB University of Connecticut Health Center http://resadm.uchc.edu/hspo/index.html

  2. Audit Purpose • Management tool to monitor: conduct of research studies & IRB review process • Promote Education concerning policies & regulations • Promote Quality Research • Monitor/improve compliance w/ policies & regulations • Optimize Protection for Subjects, PI & UCHC http://resadm.uchc.edu/hspo/index.html

  3. Types of Monitoring Visits/Audits • Random (automatic system for selection; scheduled) • Unannounced • IRB Mandated (unannounced or short-notice) • For Cause (e.g. response to complaint; unannounced or short-notice) • Follow-up audit to assess implementation of corrective actions (scheduled) • Pre-IRB approval IND audit (investigator-initiated INDs; scheduled) • Observation of Informed Consent Process http://resadm.uchc.edu/hspo/index.html

  4. Random Audit Process • Selection • Audit Notification & Scheduling Date/Time Arrangements • Audit interview/material review • Audit letter/report (may require PI response) • Submission of corrective action plan if applicable • Referral to IRB if necessary • Audit final follow-up letter if applicable http://resadm.uchc.edu/hspo/index.html

  5. Random Audit Notification • Standard electronic letter/message to PI • Arrangement of Date/Time Visit • Thorough study review (Audit Intake Form) • IRB File • Adverse Events System • IRB Minutes • Proof of CITI Training http://resadm.uchc.edu/hspo/index.html

  6. Audit • Interview w/ study’s PI/designee • Advertisements/Recruitment • Enrollment/Recruitment/Screening (eligibility, number, diversity, etc) • Consent Process • Payments, waivers, ICF copy for subjects • Study Drug / Device Accountability • Storage/maintenance of data http://resadm.uchc.edu/hspo/index.html

  7. Audit • Brief interview w/ Pharmacy, Laboratory, Radiology Departments if applicable • Review of storage of study documents & materials (samples, devices, specimens) http://resadm.uchc.edu/hspo/index.html

  8. Audit • Review of Study Drug/Device Procedure /Documentation • Pharmacy arrangements if applicable • Orders/prescriptions • Administration/use • Chart Notes • Drug/Device accountability logs • Storage & labeling • Return of drug or disposition http://resadm.uchc.edu/hspo/index.html

  9. Audit • Review of Consent Process • Informed Consent Form (required & optional elements) • Subjects’ ICFs (3-6 records) • Names of subjects & consenter/witness/parent or legally authorized representative/assent • Signatures & dates, no blank fields • Valid HIPPA Authorization form • Re-consenting documented (if applicable) http://resadm.uchc.edu/hspo/index.html

  10. Audit • Review of all study related documents • Regulatory/study binder • All submissions (initial, continuations, modifications) • Letters of Approval • Protocols & Amendments • ICFs & HIPPA Authorization Forms • Recruitment materials/subject letters http://resadm.uchc.edu/hspo/index.html

  11. Audit • Review of all study related documents (cont.) • Study Instruments/Surveys/Questionnaires • Data Collection Forms (CRFs) • Personnel responsibilities/delegation/signature logs (required if FDA oversees) • FDA 1572 (if applicable) • Advertisement/flyers • Correspondence http://resadm.uchc.edu/hspo/index.html

  12. Audit • Review of all study related documents (cont.) • DSMP/DSMB • Charter • Proof of training for research personnel • SAE reports • Deviation Log • Problem Reports http://resadm.uchc.edu/hspo/index.html

  13. Audit • Review of all study related documents (cont.) • Internal/External Visits/Audits Reports • Sponsor/MedWatch reports • Conflict of Interest (COI) Forms • Copy of certificates & licenses • Form designating back-up PI if desired • PI & back-up PI professional CV/ NIH sketch http://resadm.uchc.edu/hspo/index.html

  14. Audit • Review of Subject Charts (3-6 records) • ICF/HIPAA • Eligibility • Treatment • Study Calendar/Visit schedule • Deviations • Data quality/source documentation • AE/SAE • Data Security (labeling, codes) • Payments/Compensation http://resadm.uchc.edu/hspo/index.html

  15. Audit letter/report • Identifies & describes deviations/non-compliance and/or substantive deficiencies • Identifies areas of strength & best practices • Provides requirements for corrective action plans • Presents educational points & recommendations • Usually issued 5-10 business days following audit • Electronic Copy – no hard copies sent out • Letter cc to distribution list http://resadm.uchc.edu/hspo/index.html

  16. Corrective Action Plan & Follow-up • Corrective action plans/modification requests if needed • PI’s written response due date stated in audit letter • PI’s response to DHSPO directly to Research Compliance Monitor (RCM) • Final audit follow-up letter • Electronic Copy – no hard copies sent out http://resadm.uchc.edu/hspo/index.html

  17. Serious and/or Continuing Non-Compliance • Findings involving imminent risk to subjects immediately reported to DHSPO • If Findings Suggest Possible Serious and/or Continuing Non-Compliance • Referred to IRB for review, discussion & determination after final PI response is received • Findings may be reported out (e.g.: institutional officials, FDA, funding agency, OHRP)

  18. Minimizing Non-Compliance • Maintain Accurate Documentation • Dates & times • Appropriate signatures • Utilization of documents w/ valid-through dates • No blank fields on forms (use N.P. or N/A ) • Appropriately filled-out forms • Source Documentation/CRFs http://resadm.uchc.edu/hspo/index.html

  19. Pointers • Ensure Consistency between all study documents (protocol, IRB application, ICF, etc.) • Ensure Consistency between regulatory documents at study site & in IRB file • Modifications must be approved by IRB prior to implementing any changes http://resadm.uchc.edu/hspo/index.html

  20. Remember… • Follow protocol • Conduct study as planned, described in IRB application & explained/approved by IRB • If changes needed, submit for modification • Self-report deviations & unanticipated problems • Follow through on corrective action plans • If in doubt, ask HSPO staff

  21. Contact Information • IRB support • Patty Gneiting (exempt/expedited) x4849 • Pam Colwell (panel 1 & 3) x1019 • Donna Horne (panel 2 & 3) x4851 • Marcy Chasse (outgoing approvals) x8729 • HSPO • Deputy Director, Deb Gibb x3054 • Judy Gaffney, RCM x7555 • Monika Haugstetter, RCM x8802 http://resadm.uchc.edu/hspo/index.html

More Related